Diabetes Drugs that Reduce Cardiovascular Disease and Death: Top 10 Medical Innovations 2017

Diabetes Drugs that Reduce Cardiovascular Disease and Death: Top 10 Medical Innovations 2017

Nearly a decade ago, a wave of new diabetes drugs hit the market with promises of lowering blood sugar. They fell far short of blunting the scariest statistics for type 2 diabetes patients: Half will die from complications from cardiovascular disease. On their 65th birthdays, the odds go up to 70 percent. In 2016, a couple of new medications began dropping the mortality rates considerably. Empaglifozin proved to modify the progression of heart disease by working with the kidney while liraglutide has a comprehensive effect on many organs. Given the positive results, experts predict 2017 will mark a complete shift in the lineup of medicines prescribed for diabetes patients, as well as a new wave of research into new avenues to target type 2 diabetes and its comorbidities. With the contribution of these new drugs, more patients will live to see the benefits.

The Pearls and Pits of Jardiance: What You Need to Know

The Pearls and Pits of Jardiance: What You Need to Know

Today I want to share the pits and the pearls of Jardiance, a new medication for Type 2 Diabetes. Check out more of my videos and Subscribe to my Channel! Dr. Christina Tarantola is a pharmacist, health coach and reiki healer. She helps her clients to gain more energy, lose weight and decrease the need for medication. For more about her personalized coaching, visit www.christinatarantola.com Visit my Facebook page at: https://www.facebook.com/pages/Nutriglo-Consulting-LLC/513149028771643?ref=bookmarks Twitter: https://twitter.com/integratedRx Web: www.christinatarantola.com Subscribe to my newsletter: http://visitor.r20.constantcontact.com/manage/optin?v=001pfPluQc8rlxXsd1aVuFwYTa2EaBfAKntw2T2nY7Mph4DbxYprArYMEMP2aaO66AhzaaSsa0GHJnQ8vSs0ZQmI4wP3qVvC3ElrAIKRufeECbxLs5q4wmQtPmpxLy7Qtig01cW1_c_ZPXFeBhTb6Kchtg5qWFGEpe0 Medical disclaimer for NutriGlo Consulting: *These statements have not been evaluated by the FDA. Advice and recommendations given in this website or in personal consultation by phone, email, in-person, online coaching, or otherwise, is at the reader’s sole discretion and risk. You should see a qualified, licensed doctor before starting any skin care, nutritional, diet, stretching, and/or exercise program. Information presented on this website is not to be interpreted as kind of attempt to prescribe or practice medicine. These statements and information have not been evaluated by the Food and Drug Administration. No product offerings are intended to treat, diagnose, cure or prevent any disease. You should always consult with a competent, fully-informed medical professional or health practitioner when making decisions having to do with your health. You are advised to investigate and educate yourself about any health related actions and choices you make.

Jardiance

Jardiance

Currently the most popular drug in the family of Invokana and Farxiga, Jardiance stimulates the kidneys to expel glucose from the bloodstream into the urine. As a result patients with type 2 diabetes benefit by losing weight and improving their blood pressure. A relatively large study suggests Jardiance might also slightly reduce the risk of all cause mortality and decrease the likelihood of death from cardiovascular disease. Although these results appear statistically significant, the absolute improvement remains small at less than 3%. No reduction occurs in the incidence of heart attacks or stroke. Blood glucose and hemoglobin A1c fall only modestly.

Jardiance diabetes drug introduction movie

Jardiance diabetes drug introduction movie

Jardiace drug from Boehringer introductory movie displayed on 20 x 3 m screen in fairmont hotel Cairo - Egypt Designed by ZDesign Studios

Pits and Pearls of SGLT2 Inhibitors (Invokana, Jardiance, Farxiga)

Pits and Pearls of SGLT2 Inhibitors (Invokana, Jardiance, Farxiga)

Welcome to my channel! Thank you for sharing, liking and subscribing! Check out my new Lighten Up Transformation Program below and book your FREE 30 minute Lighten Up Call today! www.enlightenedwellnessPA.com/lightenup Today we are talking about SGLT2 inhibitors (Invokana, Farxiga, Jardiance and Steglatro.) How do these drugs work? Blocks glucose reabsorption in the kidney and increases urinary excretion of glucose by blocking sodium glucose co-transporter 2. Pits: COMMON side effects: urinary issues (UTI, fungal/yeast infections), dizziness, hypotension, hyperkalemia (especially with renal impairment), increased risk of bladder cancer (Farxiga). RARE: pancreatitis, amputations occur in 6 out of 1000 patients treated versus 3 out of 1000 with other meds. Renal impairment adjustments may be needed. Pearls: A1C drop when added to metformin 0.4 to 0.7% CV benefit: Level Evidence A: RCT trial. CANVAS trial showed Invokana use for 3.5 years when added to glucose-lowering therapy patients with high CV risk may reduce the combined end-point of CV mortality, nonfatal MI, nonfatal stroke. When the end-points where evaluated individually, there was no clinical significance. Jardiance use with CVD patients for 3 years showed decrease hospitalizations due to HF, CV death, overall death. Weight loss. Limited evidence to support how much weight loss is expected. Researchers found that actual weight loss was 2.7 times less than predicted in patients with type 2 diabetes (T2DM) on SGLT2 inhibitors. The results suggested that these patients increased their food intake, compensating for some of the energy lost through glycosuria. Average weight loss seen after 90 weeks is -3.2 +/- 4.2 kg Combinations with SGLT2 inhibitors: Invokamet Glyxambi (Jardiance/linagliptin) Synjardy (Jardiance/metformin) Medical disclaimer for Enlightened Wellness Solution: *These statements have not been evaluated by the FDA. Advice and recommendations given in this website or in personal consultation by phone, email, in-person, online coaching, or otherwise, is at the reader’s sole discretion and risk. You should see a qualified, licensed doctor before starting any skin care, nutritional, diet, stretching, and/or exercise program. Information presented on this website is not to be interpreted as kind of attempt to prescribe or practice medicine. These statements and information have not been evaluated by the Food and Drug Administration. No product offerings are intended to treat, diagnose, cure or prevent any disease. You should always consult with a competent, fully-informed medical professional or health practitioner when making decisions having to do with your health. You are advised to investigate and educate yourself about any health related actions and choices you make.

Jardiance For Type 2 Diabetes in Adults - Overview

Jardiance For Type 2 Diabetes in Adults - Overview

http://www.rxwiki.com/jardiance Ask a pharmacist your questions now! http://www.rxwiki.com/askrx/questions Jardiance is a prescription medication used to treat type 2 diabetes in adults. Jardiance is a sodium-glucose co-transporter 2 inhibitor. These work by stopping the reabsorption of glucose by the kidney, increasing glucose excretion from the body, and lowering blood sugar levels. This medication comes in tablet form and is taken once daily, in the morning, with or without food. Common side effects of Jardiance include dehydration and urinary tract infections.

New Diabetes Combo Rx Gets Go Ahead

New Diabetes Combo Rx Gets Go Ahead

http://www.dailyrxnews.com/synjardy-empagliflozin-and-metformin-hydrochloride-tablets-approved-treat-type-2-diabetes-fda The FDA approval of a new combination medication should soon bring type 2 diabetes patients a new treatment option. The US Food and Drug Administration (FDA) Friday approved Synjardy (empagliflozin and metformin hydrochloride) to treat type 2 diabetes in adults. The Boehringer Ingelheim and Eli Lilly drug is the third containing empagliflozin to receive FDA approval. The other two are Glyxambi and Jardiance.

JARDIANCE Reduce Cardiovascular Death Risks in Adults with Type 2 Diabetes Jardiance

JARDIANCE Reduce Cardiovascular Death Risks in Adults with Type 2  Diabetes Jardiance

Dr. Christopher Cannon discusses using JARDIANCE to Reduce Cardiovascular Death Risks in Adults with Type 2 Diabetes Guest Bio: Dr. Christopher Paul Cannon is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and a professor of medicine at Harvard Medical School (HMS). Dr. Cannon is the executive director of cardiometabolic trials at the Harvard Clinical Research Institute. Dr. Cannon earned his medical degree from Columbia University College of Physicians and Surgeons. He completed an internal medicine residency at New York-Presbyterian Hospital and a cardiology fellowship at BWH. Dr. Cannon is board certified in internal medicine. Segment overview: Dr. Christopher Cannon, discusses JARDIANCE, a treatment that can help reduce the risk of cardiovascular death in adults with type 2 diabetes and known cardiovascular disease. For more information about this interview, visit this link: http://healthprofessionalradio.com.au/dr-christopher-paul-cannon-jardiance/

SAFETY ALERT!! DIABETES DRUGS INVOKANA, FARXIGA, JARDIANCE, STEGLATRO

SAFETY ALERT!! DIABETES DRUGS INVOKANA, FARXIGA, JARDIANCE, STEGLATRO

Let's explore the latest in FDA Drug Safety Communications for the novel class of diabetes drugs - the SGLT2 inhibitors - INVOKANA, FARXIGA, JARDIANCE, and STEGLATRO, plus all their relatives. Check out these docs right here on YouTube who have some great diet and nutrition advice that might help you improve or even CURE Type II diabetes: Dr Ken D Berry, Dr Jason Fung, Dr Mindy Pelz, Dr Shawn Baker, Dr Sarah Hallberg, Dr Eric Berg, Dr William Davis

SGLT2 Inhibitors Explained in 3 Minutes

SGLT2 Inhibitors Explained in 3 Minutes

SGLT2 Inhibitors include empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), ertugliflozin (Steglatro)

Top Videa -  loading... Změnit krajinu
Načíst dalších 10 videí
 
 
Sorry, You can't play this video
00:00/00:00
  •  
  •  
  •  
  •  
  •  
  •  
  •  
CLOSE
CLOSE
CLOSE